74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Charles River Laboratories International Inc
Closed
SectorHealthcare
151.8 -2.4
Overview
Share price change
24h
Min
151.57
Max
158.21
Income | -332M -277M |
|---|---|
Sales | -11M 994M |
EPS | 2.43 |
Profit margin | -27.816 |
Employees | 18,300 |
EBITDA | 730K 198M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +32.44% upside |
Next Earnings | 6 May 2026 |
|---|
Market Cap | 772M 8.7B |
|---|---|
Previous open | 154.2 |
Previous close | 151.8 |
News Sentiment
By Acuity
10%
90%
9 / 351 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bullish Evidence
Charles River Laboratories International Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Charles River Laboratories International Inc Forecast
Price Target
By TipRanks
32.44% upside
12 Months Forecast
Average 205.89 USD 32.44%
High 265 USD
Low 175 USD
Based on 11 Wall Street analysts offering 12 month price targets forCharles River Laboratories International Inc - Dist in the last 3 months.
Sentiment
By Acuity
9 / 351 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Charles River Laboratories International Inc
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Live chat